CuRNA, Inc.
Records under this name other than the patents CuRNA, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 51 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,318,690 | Treatment of hemoglobin (HBF/HBG) related diseases by inhibition of natural antisense transcript to HBF/HBG Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,214,745 | Treatment of Brain Derived Neurotrophic Factor (BDNF) Related Diseases by Inhibition of Natural Antisense Transcript to BDNF Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 10,113,166 | Treatment of Filaggrin (FLG) Related Diseases by Modulation of FLG Expression and Activity Grace period ended · Low confidence | Grace period ended | Low confidence | |
| US 11,408,004 | Treatment of Sirtuin (SIRT) Related Diseases by Inhibition of Natural Antisense Transcript to a Sirtuin (SIRT) Lapsed on the fee record Ended Aug 9, 2026 · High confidence | Lapsed on the fee record | Ended Aug 9, 2026 | High confidence |
| US 10,036,014 | Treatment of Down Syndrome Gene Related Diseases by Inhibition of Natural Antisense Transcript to a Down Syndrome Gene Lapsed on the fee record Ended Jul 31, 2026 · High confidence | Lapsed on the fee record | Ended Jul 31, 2026 | High confidence |
| US 8,791,087 | Treatment of 'C Terminus of HSP70-Interacting Protein' (CHIP) Related Diseases by Inhibition of Natural Antisense Transcript to Chip Lapsed on the fee record Ended Jul 29, 2026 · High confidence | Lapsed on the fee record | Ended Jul 29, 2026 | High confidence |
| US 11,390,868 | Treatment of Filaggrin (FLG) Related Diseases by Modulation of FLG Expression and Activity Lapsed on the fee record Ended Jul 19, 2026 · High confidence | Lapsed on the fee record | Ended Jul 19, 2026 | High confidence |
| US 11,339,394 | Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene Lapsed on the fee record Ended May 24, 2026 · From the USPTO record | Lapsed on the fee record | Ended May 24, 2026 | From the USPTO record |
| US 9,970,008 | Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1 Lapsed on the fee record Ended May 15, 2026 · From the USPTO record | Lapsed on the fee record | Ended May 15, 2026 | From the USPTO record |
| US 9,957,503 | Treatment of LCAT gene related diseases by inhibition of a natural antisense transcript to LCAT Lapsed on the fee record Ended May 1, 2026 · From the USPTO record | Lapsed on the fee record | Ended May 1, 2026 | From the USPTO record |